XML 45 R35.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Strategic License and Research and Collaboration Agreements - Additional Information (Details) £ in Millions | 1 Months Ended | 3 Months Ended |
--- | --- | --- | ---
Oct. 31, 2023 USD ($) | Feb. 28, 2022 USD ($) | Nov. 30, 2015 USD ($) | Mar. 31, 2024 USD ($) | Mar. 31, 2024 GBP (£) | Mar. 31, 2023 USD ($) | Dec. 31, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Prepaid research and development costs |  |  |  | $ 20,070,000 |  |  | $ 24,297,000
Research and development expenses |  |  |  | 45,757,000 |  | $ 29,485,000 |
2015 TSRI License Agreement |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Milestones achieved |  |  |  | 0 |  |  |
Milestone Payments | $ 300,000 |  |  |  |  |  |
Accrued Royalties |  |  |  | $ 0 |  |  |
2015 TSRI License Agreement | Maximum |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Development and regulatory milestone payments |  |  | $ 1,500,000 |  |  |  |
Commercial milestone payments |  |  | $ 3,500,000 |  |  |  |
Amgen Research and Collaboration Agreement |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Collaboration agreement termination description |  |  |  | The term of the agreement is up to five years, although it will terminate after three years if the Company and Amgen do not mutually agree upon a compensation structure for years four and five. If the parties do not reach an agreement at least 30 days prior to the end of year three, the Amgen Collaboration Agreement will automatically terminate upon its third anniversary. Further, either party can terminate the Amgen Collaboration Agreement upon material uncured breach or bankruptcy by the other party, in which case all amounts that have become due through the date of termination are non-refundable. | The term of the agreement is up to five years, although it will terminate after three years if the Company and Amgen do not mutually agree upon a compensation structure for years four and five. If the parties do not reach an agreement at least 30 days prior to the end of year three, the Amgen Collaboration Agreement will automatically terminate upon its third anniversary. Further, either party can terminate the Amgen Collaboration Agreement upon material uncured breach or bankruptcy by the other party, in which case all amounts that have become due through the date of termination are non-refundable. |  |
Research and collaboration agreement quarterly payments for first two year |  |  |  | $ 50,000,000 |  |  |
Prepaid research and development costs |  |  |  | 9,400,000 |  |  | $ 6,300,000
Research and development expenses |  |  |  | 0 |  | $ 8,100,000 |
Amgen Research and Collaboration Agreement | Minimum |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Research and collaboration agreement quarterly payments for third year |  |  |  | $ 12,500,000 |  |  |
Amgen Research and Collaboration Agreement | Maximum |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Term of the agreement |  |  |  | 5 years | 5 years |  |
Vanderbilt Research Agreement |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Research and collaboration agreement quarterly payments |  | $ 1,700,000 |  |  |  |  |
Research agreement expiry date |  |  |  | 2023-09 | 2023-09 |  |
Parkinson's Research Ventures Funding Agreement |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Research and development expenses |  |  |  | $ 0 |  |  |
Funds received upon execution of agreement | £ |  |  |  |  | £ 0.9 |  |
Payments for execution of agreement |  |  |  | $ 1,100,000 |  |  |
Fund eligible to receive upon completion of certain development milestone | £ |  |  |  |  | 1.2 |  |
Maximum repayment amount agreed to pay. | £ |  |  |  |  | 8.4 |  |
Parkinson's Research Ventures Funding Agreement | Maximum |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Funds provided for preclinical research and development activities | £ |  |  |  |  | £ 2.1 |  |

X
- Definition Collaboration agreement term. + References No definition available. + Details
Name: | nmra_CollaborationAgreementTerm
Namespace Prefix: | nmra_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration agreement termination description. + References No definition available. + Details
Name: | nmra_CollaborationAgreementTerminationDescription
Namespace Prefix: | nmra_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Commercial milestone payments. + References No definition available. + Details
Name: | nmra_CommercialMilestonePayments
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development and regulatory milestone payments. + References No definition available. + Details
Name: | nmra_DevelopmentAndRegulatoryMilestonePayments
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fund eligible to receive upon completion of certain development milestone. + References No definition available. + Details
Name: | nmra_FundEligibleToReceiveUponCompletionOfCertainDevelopmentMilestone
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Funds provided for pre-clinical research and development activities. + References No definition available. + Details
Name: | nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Funds received upon execution of agreement. + References No definition available. + Details
Name: | nmra_FundsReceivedUponExecutionOfAgreement
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum repayment amount agreed to pay. + References No definition available. + Details
Name: | nmra_MaximumRepaymentAmountAgreedToPay
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone Payments + References No definition available. + Details
Name: | nmra_MilestonePayments
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestones achieved. + References No definition available. + Details
Name: | nmra_MilestonesAchieved
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payments for execution of agreement. + References No definition available. + Details
Name: | nmra_PaymentsForExecutionOfAgreement
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research agreement expiry date. + References No definition available. + Details
Name: | nmra_ResearchAgreementExpiryDate
Namespace Prefix: | nmra_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Collaboration Agreement Quarterly Payments + References No definition available. + Details
Name: | nmra_ResearchAndCollaborationAgreementQuarterlyPayments
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and collaboration agreement quarterly payments for first two years. + References No definition available. + Details
Name: | nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research and collaboration agreement quarterly payments for third year. + References No definition available. + Details
Name: | nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details
Name: | us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_TwoThousandAndFifteenTsriLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_VanderbiltSponsoredResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_ParkinsonsResearchVenturesFundingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |